Repaglinide
Repaglinide
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment
Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially...